The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2020 | Updates from the ECHELON-1 study
David J. Straus, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, updates us on long term results of the ECHELON-1 study (NCT01712490), evaluating brentuximab vedotin, an antibody-drug conjugate, with chemotherapy for stage III/IV classical Hodgkin lymphoma. Furthermore, Dr Straus elaborates on an ongoing study evaluating BV + ABD against nivolumab + ABD. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
